NasdaqGS - Nasdaq Real Time Price USD

Neurocrine Biosciences, Inc. (NBIX)

Compare
151.03 -1.24 (-0.81%)
As of 2:42 PM EDT. Market Open.
Loading Chart for NBIX
DELL
  • Previous Close 152.27
  • Open 152.50
  • Bid 150.90 x 100
  • Ask 151.16 x 100
  • Day's Range 150.20 - 152.57
  • 52 Week Range 103.63 - 157.98
  • Volume 137,280
  • Avg. Volume 797,892
  • Market Cap (intraday) 15.25B
  • Beta (5Y Monthly) 0.37
  • PE Ratio (TTM) 45.49
  • EPS (TTM) 3.32
  • Earnings Date Oct 29, 2024 - Nov 4, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date Dec 29, 1995
  • 1y Target Est 171.88

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL ? Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

www.neurocrine.com

1,500

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NBIX

View More

Performance Overview: NBIX

Trailing total returns as of 8/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NBIX
14.63%
S&P 500
17.98%

1-Year Return

NBIX
40.47%
S&P 500
27.73%

3-Year Return

NBIX
61.86%
S&P 500
25.90%

5-Year Return

NBIX
52.31%
S&P 500
95.51%

Compare To: NBIX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NBIX

View More

Valuation Measures

Annual
As of 8/26/2024
  • Market Cap

    15.37B

  • Enterprise Value

    14.58B

  • Trailing P/E

    45.84

  • Forward P/E

    30.40

  • PEG Ratio (5yr expected)

    0.52

  • Price/Sales (ttm)

    7.38

  • Price/Book (mrq)

    6.12

  • Enterprise Value/Revenue

    6.88

  • Enterprise Value/EBITDA

    23.73

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    16.00%

  • Return on Assets (ttm)

    11.51%

  • Return on Equity (ttm)

    15.55%

  • Revenue (ttm)

    2.12B

  • Net Income Avi to Common (ttm)

    339.2M

  • Diluted EPS (ttm)

    3.32

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.04B

  • Total Debt/Equity (mrq)

    11.62%

  • Levered Free Cash Flow (ttm)

    496.06M

Research Analysis: NBIX

View More

Company Insights: NBIX

Research Reports: NBIX

View More

People Also Watch